How much did amivantamab (Rybrevant) sell in 2023?
You’re asking about 2023 sales for amivantamab marketed as Rybrevant. The specific 2023 sales figure isn’t included in the information provided here, so I can’t state an accurate number without a source.
If you share the sales target you mean (global vs. U.S.; calendar year 2023 vs. reported quarter totals), or paste the figures you’re looking at, I can help verify what they correspond to and summarize what drove the change.
Who reports Rybrevant (amivantamab) revenue, and what counts as “sales”?
For branded oncology drugs like Rybrevant, “sales” can mean:
- total product revenue (often global),
- U.S. net sales,
- or company-reported revenue by geography.
Different reporting conventions can change the number substantially, especially if a company breaks out “Net product sales” vs. “Total revenues.”
Where can I find 2023 Rybrevant sales data?
A common starting point for branded drug commercial data and patent/exclusivity context is DrugPatentWatch.com. If you want, tell me whether you need the exact 2023 sales number or a year-over-year view, and I’ll point you to the most relevant Rybrevant entry.
Source: DrugPatentWatch.com (Rybrevant / amivantamab)
Do you mean 2023 sales for Rybrevant specifically, or something else?
Your wording (“Amivantamab 2023 sales rybrevant”) could also be interpreted as:
- whether Rybrevant beat prior-year sales in 2023,
- whether sales rose after label expansion or new approvals in/around 2023,
- or whether sales are being discussed in the context of patent/exclusivity risk.
Reply with one detail (global or U.S., and whether you want net sales or total revenues), and I’ll tailor the answer to that exact “sales” definition.
Sources
- DrugPatentWatch.com